Media coverage about Urogen Pharma (NASDAQ:URGN) has been trending somewhat positive this week, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Urogen Pharma earned a daily sentiment score of 0.01 on Accern’s scale. Accern also gave media headlines about the company an impact score of 47.7605453336634 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Several analysts recently commented on the company. Oppenheimer set a $75.00 target price on Urogen Pharma and gave the company a “buy” rating in a report on Tuesday, August 14th. Cowen reiterated a “buy” rating on shares of Urogen Pharma in a report on Tuesday, August 14th. ValuEngine upgraded Urogen Pharma from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. Finally, Zacks Investment Research upgraded Urogen Pharma from a “sell” rating to a “hold” rating in a report on Tuesday, May 15th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $57.00.

URGN traded up $1.28 during trading on Friday, hitting $44.29. The company’s stock had a trading volume of 45,828 shares, compared to its average volume of 71,248. Urogen Pharma has a twelve month low of $17.27 and a twelve month high of $69.57. The firm has a market cap of $604.37 million, a PE ratio of -20.70 and a beta of 2.11.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Tuesday, August 14th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by ($0.25). Urogen Pharma had a negative net margin of 470.54% and a negative return on equity of 44.24%. The business had revenue of $0.36 million during the quarter. equities research analysts expect that Urogen Pharma will post -4.16 EPS for the current fiscal year.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Read More: Diversification

Insider Buying and Selling by Quarter for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with's FREE daily email newsletter.